| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:TFCP2L1-IN-1
CAS:364621-46-5
Package:10mg/RMB 1980;50mg/RMB 4990
|
| Company Name: |
VITAS-M LABORATORY, LTD.
|
| Tel: |
+7 495 939 48 31 |
| Email: |
|
| Products Intro: |
Product Name:3-bromo-N-[(2-methylphenyl)carbamothioyl]benzamide
CAS:364621-46-5
Purity:90%+ Package:1mg
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Email: |
info@specs.net |
| Products Intro: |
|
|
| | N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Basic information |
| | N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Chemical Properties |
| density | 1.511±0.06 g/cm3(Predicted) | | form | Solid | | pka | 8.67±0.70(Predicted) | | color | Off-white to light yellow |
| | N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Usage And Synthesis |
| Uses | TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib (HY-10201) to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells[1]. | | References | [1] Qiu D, et al. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. Oncogenesis. 2024 Sep 12;13(1):33. DOI:10.1038/s41389-024-00534-1 |
| | N-(3-bromobenzoyl)-N'-(2-methylphenyl)thiourea Preparation Products And Raw materials |
|